Results 181 to 190 of about 1,206,776 (294)

Impact of Relative Dose Intensity of Enfortumab Vedotin for Advanced Urothelial Carcinoma. [PDF]

In Vivo
Furubayashi N, Negishi T, Mochida M, Kijima A, Katsuki H, Nakamura M.   +5 more
europepmc   +1 more source

Dose intensity for induction in acute myeloid leukemia: what, when, and for whom? [PDF]

Haematologica, 2021
McCurdy SR, Luger SM.
europepmc   +1 more source

Development of a Prediction Model for Progression Risk in High‐Grade Gliomas Based on Habitat Radiomics and Pathomics

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To investigate the value of constructing models based on habitat radiomics and pathomics for predicting the risk of progression in high‐grade gliomas. Methods This study conducted a retrospective analysis of preoperative magnetic resonance (MR) images and pathological sections from 72 patients diagnosed with high‐grade gliomas (52 ...
Yuchen Zhu, Yuxi Gong, Weilin Xu, Xingjian Sun, Gefei Jiang, Lei Qiu, Kexin Shi, Mengxing Wu, Yinjiao Fei, Jinling Yuan, Jinyan Luo, Yurong Li, Yuandong Cao, Minhong Pan, Shu Zhou   +14 more
wiley   +1 more source

Real-world outcome and dose intensity of Pola-R-CHP versus R-CHOP/R-THP-COP in newly diagnosed diffuse large B-cell lymphoma: a single-center, retrospective cohort study. [PDF]

BMC Cancer
Fujita K, Kajiya K, Lee S, Morishita T, Nonogaki S, Miwa N, Hara T, Tsurumi H.   +7 more
europepmc   +1 more source

Spinal Cord Infarction Versus Idiopathic Transverse Myelitis: Clinical, Radiological, and Functional Insights From a Retrospective Cohort Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Introduction Spinal cord infarction (SCI) is a rare but devastating myelopathy, characterized by a high disability rate and an unfavorable prognosis. It has often been underdiagnosed and misdiagnosed as idiopathic transverse myelitis (ITM). This study aimed to describe the clinical features, radiological biomarkers, treatments, and functional ...
Zeqiang Ji, Jianlong Zhang, Yiming Shi, Shiyu Shan, Yang Du, Guangshuo Li, Ying Jin, Yani Zhang, Chuanying Wang, Yijun Lin, Yuhao Guo, Decai Tian, Xingquan Zhao, Tian Song   +13 more
wiley   +1 more source

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.

Blood
Al-Sawaf O, Fürstenau M, Giza A, Robrecht S, von Tresckow J, Fink AM, Simon F, Tausch E, Schneider C, Sivcheva L, Schwarer A, Loscertales J, Weinkove R, Strumberg D, Kilfoyle A, Juliusson G, da Cunha-Bang C, Illmer T, Gregor M, Thornton P, Janssens A, Tadmor T, Lindström V, Staber P, Levin MD, Wendtner CM, Kreuzer KA, Ritgen M, Stilgenbauer S, Kater AP, Niemann C, Fischer K, Eichhorst B, Hallek M.   +33 more
europepmc   +1 more source

Oncoral Follow-Up for Outpatients Treated with Oral Anticancer Drugs Assessed by Relative Dose Intensity. [PDF]

Pharmaceuticals (Basel)
Larbre V, Ranchon F, Maucort-Boulch D, Coz E, Herledan C, Caffin AG, Baudouin A, Maire M, Romain-Scelle N, Vacheron CH, Karlin L, Salles G, Ghesquières H, Rioufol C.   +13 more
europepmc   +1 more source

Clustering Algorithm Reveals Dopamine‐Motor Mismatch in Cognitively Preserved Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To explore the relationship between dopaminergic denervation and motor impairment in two de novo Parkinson's disease (PD) cohorts. Methods n = 249 PD patients from Parkinson's Progression Markers Initiative (PPMI) and n = 84 from an external clinical cohort.
Rachele Malito, Chiara Meneghini, Alice Galli, Luca Gallo, Pierfrancesco Mitrotti, Paola Dimartino, Marianna Inglese, Cinzia Zatti, Alessandro Lupini, Andrea Pilotto, Alessandro Padovani, Micol Avenali, Enza Maria Valente, Cristina Tassorelli, Silvia P. Caminiti   +14 more
wiley   +1 more source

Landscape analysis of adverse events and dose intensity for FDA approved oncology small molecules. [PDF]

Cancer Chemother Pharmacol
Collins KP, Yin D, Pithavala YK, Mittapalli RK.   +3 more
europepmc   +1 more source

Neuroinflammation in GAD65 Antibody‐Associated Epilepsy Measured Using [18F]DPA‐714 PET/MRI

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The timing for initiating immunotherapy in patients with glutamic acid decarboxylase 65 (GAD65) antibody‐associated epilepsy is a challenge. We used the translocator protein radioligand [18F]DPA‐714 and PET to evaluate brain microglial activation.
Jingjing Chen, Yuying Zhang, Heyu Zhang, Jinming Zhang, Ningning Wang, Xintong Guo, Yicong Liu, Yue Liu, Xiangsong Zhang, Ziyi Chen, Guanzhong Ni   +10 more
wiley   +1 more source